Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells

Lei Zhang1,2,3, Biwei Ye2,4, Yunfeng Lin2,4, Yi-Dong Li1, Jing-Quan Wang1, Zhuo Chen2,3, Feng-Feng Ping5* and Zhe-Sheng Chen1*

1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States, 2State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, China, 3University of Chinese Academy of Sciences, Beijing, China, 4Fujian Agriculture and Forestry University, Fuzhou, China, 5Department of Reproductive Medicine, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China

The efficacy of cancer chemotherapy can be attenuated or abrogated by multidrug resistance (MDR) in cancer cells. In this study, we determined the effect of the CDK4/6 inhibitor, ribociclib (or LEE011), on P-glycoprotein (P-gp)-mediated MDR in the human epidermoid carcinoma MDR cell line, KB-C2, which is widely used for studying P-gp-mediated MDR in cancers. The incubation of KB-C2 cells with ribociclib (3–9 µM) increased the efficacy of colchicine, a substrate for P-gp. The cell expression of P-gp was downregulated at both translation and transcription levels. Furthermore, ribociclib produced a 3.5-fold increase in the basal activity of P-gp ATPase, and the concentration required to increase basal activity by 50% (EC50) was 0.04 µM. Docking studies indicated that ribociclib interacted with the drug-substrate binding site of P-gp. The short-term and long-term intracellular accumulation of doxorubicin greatly increased in the KB-C2 cells co-cultured with ribociclib, indicating ribociclib inhibited the drug efflux activity of P-gp. The results of our study indicate that LEE011 may be a potential agent for combined therapy of the cancers with P-gp mediated MDR.

Keywords: cancer, ribociclib-LEE011, multidrug resistance (MDR), cyclin dependent kinases, CDKs 4 and 6, P-glycoprotein (ABCB1 protein)

INTRODUCTION

The cyclin-dependent kinases (CDKs) are members of serine-threonine kinases that regulate the cell cycle and affect cell proliferation and apoptosis (Braun et al., 1998; Diani et al., 2009; Szwarcwort-Cohen et al., 2009; Chung and Bunz, 2010; Hirai et al., 2016; Li et al., 2015; Duan et al., 2015; Rainey et al., 2016; Czudor et al., 2018; Menzl et al., 2019; Loyer and Trembley, 2020; Robert et al., 2020). They bind to their corresponding cyclin, forming a cyclin-CDK complex, where CDKs catalyze the phosphorylation of certain serine and threonine residues in target proteins, leading to regulation of gene transcription and cell division (Rank et al., 2000). The downregulation of CDK4/6 promotes cellular apoptosis, suppresses tumor proliferation, migration, and invasion (Liu et al., 2014; Guo et al., 2020; Hu et al., 2020). Currently, the CDK4/6 inhibitors, ribociclib, palbociclib and abemaciclib, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2-negative, advanced or metastatic (Kwapisz, 2017; Tripathy et al., 2017) In cell-free assays, all three compounds are potent inhibitors of CDK4 and CDK6 (IC50 values from 2 to 39 nM) and...
ribociclib and abemaciclib inhibit CDK9 (IC_{50} of 1.51 μM and 57 nM, respectively) (Tripathy et al., 2017). Ribociclib induces the dephosphorylation of cyclin Rb, producing G_{1} phase cell cycle arrest (Aristizabal Prada et al., 2018; Tai et al., 2019). In addition, ribociclib can 1) overcome the resistance of OML1-R cancer cells to radiation (Tai et al., 2019) and 2) increase the anti-tumor efficacy of 5-fluorouracil or everolimus by downregulating the activity of the PI3K-Akt-mTOR and Ras-Raf-MEK-ERK pathways (Aristizabal Prada et al., 2018). Currently, the mechanisms involved in the reversal of MDR cancer by CDK4/6 inhibitors remains to be elucidated (Aristizabal Prada et al., 2018).

P-glycoprotein (P-gp/ABCB1) is an ATP-binding cassette (ABC) transporter that extrudes various anticancer drugs (e.g., paclitaxel, etoposide, vincristine, and doxorubicin) from cancer cells, as well as various endogenous molecules (Kathawala et al., 2015). The structure of P-gp consists of two symmetrical transmembrane domains (TMDs) formed by a group of helices and two cytoplasmic nucleotide-binding domains (NBDs) in the form of a dimer occluding two ATPs, where the hydrolysis of ATP catalyzes the transport of P-gp substrates out of the cell (Kim and Chen, 2018). The overexpression of P-gp by various cancers can produce multidrug resistance (MDR), defined as the resistance to anticancer drugs that have distinct structures and differing mechanisms of action (Kathawala et al., 2015).

It has been reported that P-gp can significantly decrease the levels of ribociclib in the brain, suggesting that its efficacy may be limited by cancer cells that overexpress P-gp (Martinez-Chavez et al., 2019). Recently, it has been reported that ribociclib reverses the resistance to daunorubicin mediated by P-gp in acute myeloid leukemia cells by interacting with P-gp and inhibiting its efflux activity (Sorf et al., 2020). However, it remains to be ascertained if ribociclib reverses P-gp mediated MDR in solid tumor cells. Therefore, in this study, we determined the effect of ribociclib on P-gp-mediated MDR in cancer, by inhibiting the expression and the drug efflux activity of P-gp in the human epidermoid carcinoma MDR cell line, KB-C2. Our results indicated that ribociclib has effects on the ATPase activity of P-gp and, through direct interaction with P-gp, attenuates the activity of P-gp to extrude its substrate drugs, like colchicine and doxorubicin, further enhances the anticancer therapy efficacy of these drugs.

**MATERIALS AND METHODS**

**Cells, Plasmids, and Chemicals**

The human epidermoid carcinoma cell line, KB-3-1, was used as the parental cell line. KB-C2, an MDR cell line that is resistant to colchicine due to the overexpression of P-gp, was created by exposing KB-3-1 cells to increasing concentrations of colchicine over a period of at least 2 months (Akiyama et al., 1985; Yoshimura et al., 1989). Both cell lines were kindly provided by Dr Shinichi Akiyama (Kagoshima University, Kagoshima, Japan). KB-3-1 and KB-C2 cells and their CDK4- and CDK6-deleted sublines were cultivated with DMEM supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified incubator containing 5% CO_{2} at 37°C. CRISPR/Cas9 all-in-one plasmids, encoding single guide RNA (sgRNA) and Cas9, were purchased from GeneCopoeia Inc (Rockville, MD). Because KB-C2 cells are widely used for studying P-gp-mediated MDR in cancers, KB-C2 cells were used to determine the reversal of P-gp-mediated MDR.

Ribociclib was kindly provided by ChemieTek (Indianapolis, IN). Paclitaxel, colchicine, and doxorubicin were purchased from Sigma Chemical Co. (St. Louis, MO). Mouse anti-P-gp, HRP ligated or fluorescent secondary rabbit or goat-anti mouse antibodies, were purchased from Invitrogen, Thermo Fisher (Carlsbad, CA). Mouse-anti-CDK4 and CDK6 antibodies were purchased from R&D Systems (Minneapolis, MN). All other reagents were purchased from VWR International (West Chester, PA).

**Determination of Cell Viability: MTT Assay**

Exponentially growing cells were seeded into 96 well plates at 5 × 10^{3} cells/well. These experiments were conducted in triplicate. After 72 h of incubation, 20 μl of MTT (5 mg/ml) was added to each well. After incubation for an additional 4 h, the medium containing MTT was discarded and replaced with 150 μl of DMSO. The plates were gently shaken until the dark blue-purple crystal were completely dissolved in DMSO. The absorbance was measured at a wavelength of 490 nm, using an ELx 800 Universal Microplate Reader (Bio-Tek, Inc. Winooski, VT). The relative survival rate (%) for the cells was analyzed using the SPSS 20 program (SPSS Inc., Chicago, IL) and the survival rate - drug concentration curves were generated using Origin 9.0 software (OriginLab corporation, Northampton, MA). The concentration of drug required to inhibit cell viability by 50% (IC_{50} value) was determined using Origin 9.0 software.

**Determination of the Efficacy of Ribociclib to Reverse MDR in Human Epidermoid Carcinoma KB-C2 Cancer Cells**

Cells were seeded into 96-well plates (5 × 10^{3} cells per well) and cultured overnight. The cells were incubated with ribociclib (0, 0.3, 1 and 3 μM) for 1 or 2 h, followed by incubation with gradient concentrations of colchicine and paclitaxel, which are substrates for the P-gp transporter. The IC_{50} values of the anti-cancer drugs were determined using the MTT assay as described above.

**Western Blot Assay**

Parental KB-3-1 cells and MDR KB-C2 cells were incubated with 9 μM of ribociclib for 2 h and co-cultured with paclitaxel or colchicine for 24–72 h. Western blot and immune-fluorescence (IF) assays were conducted to determine the effect of ribociclib on the expression of the P-gp protein. For the Western blot assay, the cells were lysed with SDS lysis reagent and separated on a gradient polyacrylamide gel (4%–20%, containing 0.1% SDS). The proteins on the SDS-PAGE gel were transferred to a PVDF membrane. After blocking with 5% milk, the membrane was washed with TBST buffer (150 mM NaCl, 10 mM Tris pH 8.0, 0.1% v/v Tween20) three times, incubated with mouse anti-P-gp
antibody at 4°C for 2 h, adequately washed with TBST, and incubated with goat anti-mouse IgG-HRP (horseradish peroxidase) at RT for 2 h. The membrane was then washed with TBST four times and exposed to the SignalFire™ ECL Reagent developing reagent (Cell Singing Technology, Danvers, MA), and the results were quantified using an Al600 RGB GEL Imaging System (GE, Fairfield, CT) set for the chemiluminescence mode.

**RT-Quantitative-PCR Analysis of ABCB1 Transcription**

RT-PCR of ABCB1 mRNA level was performed to investigate the influence of ribociclib on the ABCB1 expression on the transcription level. Ribociclib (9 µM) showing the effect of reversing ABCB1 mediated MDR in cancer cells was added to the cell culture medium. The cells cultured without ribociclib were set as control. After 48 h of cell culture, the cells were sampled for mRNA extraction and RT-q-PCR (QuantStudio™ 5 Real-Time PCR System, ThermoFisher Scientific, CA). ABCB1 and GAPDH were the objective and internal reference genes, respectively. Primers for amplification of ABCB1 gene were: GAAAGTGAAAAAGGTGTG (Forward), and CTGGCGCTTTGTTCCA (Reverse). Primers for amplification of GAPDH gene were ATTAGCCTCAACTACA (Forward), and AGAGATGATGACCCTT (Reverse). Expression deviation was calculated according to the formula: Ratio Sample/Control = 2−ΔΔCT, where Ct value was automatically calculated by QuantStudio™ Design and Analysis Software v1.3.1 according to the ΔRn-Cycle curve.

**ATPase Activity Assay**

The ATPase activity of P-gp was determined using the PREDEASY ATPase Kits (SOLVO Biotechnology, Szeged, Hungary), according to the manufacturer’s protocol (Ambudkar, 1998). Briefly, the membranes (20 µg) were incubated in assay buffer (50 mM of MES at pH 6.8, 50 mM of KCl, 5 mM of sodium azide, 2 mM of EGTA, 2 mM of DTT, 1 mM of ouabain and 10 mM of MgCl2). The membrane vesicles from Sf9 cells were provided by the manufacturer, expressing high levels of human ABCB1, were incubated with ribociclib (0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 5, 10 and 20 µM) for 3 min. ATP hydrolysis was initiated by adding 5 mM of Mg-ATP and the reaction was terminated using a 5% SDS solution. Subsequently, the light absorption was measured at 800 nm using a Bio-Rad SmartSpec 30,000 UV/Vis spectrophotometer (Bio-Rad Laboratories, Hercules, CA).

**Efflux of Doxorubicin by Accumulation Assay**

Because doxorubicin is a fluorescent substrate that can be extruded from cancer cells by the P-gp transporter (Mi et al., 2010), its intracellular accumulation was used to determine if ribociclib can directly inhibit the efflux function of the P-gp transporter, thereby increasing the accumulation of doxorubicin. The parental and MDR cells were incubated with 9 µM of ribociclib for 1 h. Doxorubicin (0.2 µM) was added and co-incubated with the cells for 2 h. This incubation period and the relatively low concentration of doxorubicin were used to maintain cell viability. The cells were gently washed with PBS buffer three times and lysed using SDS lysis reagent (50 mM, pH 8.0 Tris, 1% SDS, 2 mM of sodium pyrophosphate, 25 mM of β-glycerophosphate, 1 mM of EDTA, 1 mM of Na3VO4 and 0.5 µg/ml of leupeptin). The fluorescence intensity, an indicator of doxorubicin accumulation, was determined using a SynergyTM 4 Multi-Mode Microplate Reader (Bio Tek Instruments, Inc. VT, Excitation/Emission: 450/550 nm).

For the long-term evaluation of the efflux of doxorubicin, cells were seeded at 3 × 10^3 cells per well, cultured for 8 h, and incubated with 9 µM of ribociclib and doxorubicin (1 µM for the MDR KB-C2 cells and 0.1 µM for drug-sensitive KB-3-1 cells to maintain MDR and cell viability above 60%) for 72 h. Because the membrane of the dead or severely apoptotic cells was damaged, which could lead to the inaccurate quantification of the intercellular doxorubicin levels, the distribution of doxorubicin was determined in triplicate, using fluorescent microscopy.

**Docking Analysis of the Interaction of Ribociclib With CDK4, CDK6 and the P-gp Transporter**

We first determined the transcripts for the P-gp and CDK4/6 proteins in the KB-C2 cell line. According to the open reading frame (ORF) sequences detected in the major transcripts of P-gp in KB-C2 cell line, the structure was achieved by structure modelling using a Swiss model platform (https://swissmodel.expasy.org/). The interactions between ribociclib and P-gp, CDK4 or CDK6 were calculated using HEX 8.0 software (LORIA/Inria Nancy Research Centre in Nancy, France),
based on the most stable calculated structures of the complexes by molecular docking (Kaczor et al., 2013). PyMOL (version 1.8. x) was used to analyze the data and determine the most stable complex structures, binding positions (such as residues or chemical groups) and interactions.

RESULTS

**Ribociclib Significantly Increases the Efficacy of Colchicine in KB-C2 Cancer Cells Overexpressing the P-gp Transporter**

We conducted experiments to determine if ribociclib could increase the efficacy of colchicine (i.e., reversing resistance to colchicine) in MDR KB-C2 cancer cells. As previously reported, colchicine potently decreased (IC$_{50}$ = 13.15 nM) the viability of the colchicine-sensitive KB-3-1 cancer cells (Figure 1). In contrast, the IC$_{50}$ value for colchicine was 4.98 µM in the colchicine-resistant KB-C2 cancer cells, indicating these cells were almost three orders of magnitude more resistant to colchicine compared to the parental KB-3-1 cancer cells (Figure 1).

Ribociclib non-significantly decreased the IC$_{50}$ value of colchicine in the KB-3-1 cancer cells, whereas in the colchicine-resistant KB-C2 cancer cells, 9 µM of ribociclib significantly decreased the IC$_{50}$ of colchicine in KB-C2 cancer cells (Figure 1). These results suggested that the resistance of KB-C2 cancer cells to colchicine, which was mediated by the overexpression of the P-gp transporter$^{36}$, could be partially attenuated by ribociclib (Figure 1).

**Ribociclib Significantly Down-Regulates the Expression of the P-gp Transporter**

It is possible that ribociclib increases the efficacy of colchicine in KB-C2 cancer cells by affecting the expression of the P-gp protein. Therefore, we used Western blotting to determine the effect of ribociclib on P-gp expression. Our results indicated the incubation of KB-C2 cancer cells with 9 µM (a non-toxic concentration) of ribociclib for 72 h produced a significant decrease in the expression of P-gp protein levels compared to cells incubated with vehicle (Figure 2A). The remaining P-gp transporters expressed by the KB-C2 cells most likely mediated the lowered drug resistance produced by P-gp (Figure 2A). In contrast, P-gp protein expression was not significantly altered in KB-3-1 cancer cells incubated with 9 µM of ribociclib compared to cells incubated with vehicle (Figure 2A).

Treatment with ribociclib remarkably downregulated ABCB1 transcription in the KB-C2 cells (Figure 2B). Approximately 5.6% of the ABCB1 mRNA amounts was detected in the cells treated with ribociclib (9 µM), as compared with that detected in the cells without ribociclib treatment. This conclusion was coherent with the that supported by Western blot (Figure 2B). This phenomenon implied that the ribociclib down regulated P-gp at both the translational and transcriptional levels.

**Ribociclib’s Interaction With a Human Homology Model of the P-gp Transporter**

Although ribociclib showed decent inhibition activity when it binds CDK4 or CDK6 (Supplementary Figures S1–S4), we also performed docking analysis experiments to determine if ribociclib interacted with the P-gp transporter and if so, what chemical interactions were involved. Our results indicated that a strong interaction between P-gp and ribociclib existed. Docking studies indicated that ribociclib interacted with the drug-substrate binding site of P-gp, and had a Docking Score/Etotal (Eforce + Eshape, Kalaiselvi et al., 2015) of - 271.06. The molecular modeling indicated electrostatic interactions between N,N-dimethylamide cluster (positively charged with a proton at physiological conditions) in ribociclib and E273 and E1129 (with negative charges), in a trough-like structure between TMDs and NBDs in P-gp, which is adjacent to the interphase of the inner membrane (Figure 3, Figure 4). Since ribociclib was estimated to bind in a non-representative, drug-substrate pocket of P-gp, it was unknown as to whether this interaction results in a
change in the efflux function of P-gp, which is frequently associated with a change in the ATPase activity of P-gp and the intracellular accumulation of antitumor drugs (Zhang et al., 2020). Therefore, we conducted experiments to determine if ribociclib affected ATPase activity.

**Ribociclib Increases the ATPase Activity of the P-gp Transporter**

Although ribociclib has been reported to be highly efficacious in inhibiting CDK4/6 (Kwapisz, 2017; Tripathy et al., 2017), it remains to be elucidated whether ribociclib interacts with P-gp. Therefore, we conducted experiments to determine if ribociclib 1) interacts directly with P-gp and alters the efflux activity and 2) alters ATPase activity of human P-gp in the membrane vehicles.

Studies have shown that P-gp transporter hydrolyzes ATP, which is involved in drug efflux (Kim and Chen, 2018) and ATPase activity can be stimulated or inhibited by various P-gp substrates (Feng et al., 2020; Wu et al., 2020). It has been postulated that the stimulation of the P-gp ATPase activity by an experimental compound suggests that it is interacting with the transporter at the drug-substrate binding site (Zhang et al., 2020). Therefore, we determined the effect of various concentrations of ribociclib on P-gp ATPase activity. The incubation of membrane vesicles from sf9 insect cells (which express high levels of P-gp) with ribociclib (0.05–20 µM) produced a maximal increase of 3.5-fold in the basal activity of the P-gp transporter ATPase and the EC50 value was 0.04 µM (Figure 5A). The stimulation of P-gp transporter ATPase activity by ribociclib suggests that it may interact with the transporter at the drug-substrate binding site, although this remains to be definitively proven.

**The Effect of Ribociclib on the Intracellular Accumulation of Doxorubicin in KB-3-1 and KB-C2 Cancer Cells**

It is possible that ribociclib reverses the drug resistance of KB-C2 cancer cells by inhibiting the efflux function of P-gp. Therefore, we determined the effect of ribociclib (using a 2 h incubation period) on the intracellular accumulation on doxorubicin, a substrate for the P-gp transporter, in KB-C2 cancer cells. As previously reported (Zhang et al., 2020), the accumulation of doxorubicin was significantly greater in the parental cell line, KB-3-1, compared to MDR KB-C2 cells, which overexpress the P-gp transporter (Figure 5B) (Akiyama et al., 1985; Yoshimura et al., 1989). Doxorubicin accumulation was significantly increased in KB-C2 cancer cells incubated with 9 µM of ribociclib compared to cells incubated with vehicle (Figure 5B). In contrast, doxorubicin accumulation in the parental KB-3-1 cells, which do not overexpress the P-gp transporter, was not significantly altered by 9 µM of ribociclib. The relationship between the interaction of
ribociclib with the P-gp transporter and its inhibition of drug efflux and increase in ATPase activity is summarized in Figure 5C.

These results indicated that ribociclib increases the ATPase activity of P-gp and inhibits the drug-efflux function of P-gp, suggesting that ribociclib can interact with P-gp directly, which may contribute to the reversal of P-gp-mediated MDR in KB-C-2 cells.

The Effect of the Incubation of KB-3-1 and KB-C2 Cancer Cells With Ribociclib for 72 h on the Intracellular Accumulation of the P-gp Transporter Substrate, Doxorubicin

These studies were conducted to ascertain if the prolonged incubation (72 h) of KB-3-1 and KB-C2 cancer cells with ribociclib would inhibit the efflux of doxorubicin. The incubation of the parental KB-3-1 cells with 9 µM of ribociclib for 72 h did not significantly alter the intracellular accumulation of doxorubicin compared to cells incubated with vehicle (Figure 6). We concluded that the presence of ribociclib had no effect on the accumulation of DOX within KB-3-1 cells, which did not express P-gp and could not extrude DOX efficiently (Zhang et al., 2022). In contrast, doxorubicin accumulation was significantly increased in the KB-C2 cells incubated with 9 µM of ribociclib compared to cells incubated with vehicle (Figure 6). Thus, the accumulation of doxorubicin in the KB-C2 cells that overexpress the P-gp transporter is significantly increased after 2 or 72 h of incubation with 9 µM of ribociclib, suggesting that ribociclib increases the intracellular accumulation of doxorubicin by inhibiting the efflux function of P-gp in KB-C2 cells.

DISCUSSION

Cancers with multidrug resistance caused by overexpression of P-gp are one of the major causes for failure of chemotherapy. Seeking for inhibitors of P-gp is an applicable approach for improving the efficacy of MDR treatment. As previously reported, KB-C2 cancer cells, which overexpress P-gp, were highly resistant to colchicine, a substrate for P-gp (Yang et al., 2014). Ribociclib, at 9 µM, a concentration that did not affect cell viability, significantly decreased the IC50 value of colchicine (i.e., decreased drug resistance) in the KB-C2 cells, whereas it had no significant effect on the efficacy of colchicine in the parental KB-3-1 cells (Figure 1). To our knowledge, this is the first study to show that ribociclib decreases resistance of KB-C2 cancer cells to colchicine. Subsequently, we conducted studies to determine the mechanism(s) by which ribociclib reverses resistance to the P-gp substrates, colchicine and doxorubicin, in human epidermoid carcinoma KB-C2 cells, which have been frequently used to study P-gp-mediated MDR in cancers (Akiyama et al., 1985; Yoshimura et al., 1989). It is possible that ribociclib could reverse resistance by inhibiting the efflux function and/or the expression of the P-gp transporter.
thereby increasing the intracellular concentration of substrate drugs. Our results indicated that, the intracellular accumulation of doxorubicin, a substrate of P-gp transporter, was significantly decreased in the drug resistant KB-C2 cancer cells compared to the KB-3-1 cancer cells. The incubation of KB-C2 cancer cells with 9 µM of ribociclib, for 2 or 72 h, produced a 2-fold increase in the accumulation of doxorubicin in KB-C2 cells compared to vehicle (Figure 5). However, ribociclib did not significantly alter the concentration of doxorubicin in KB-3-1 cancer cells, which do not overexpress the P-gp transporter. Previously, it has been reported that abemaciclib, a CDK4/6 inhibitor (Iriyama et al., 2018), increased the intracellular accumulation of doxorubicin by competitively inhibiting P-gp - or ABCG2-mediated drug efflux in cells overexpressing these transporters (Wu et al., 2017).

These data tentatively suggested that ribociclib can reverse resistance to P-gp substrates in KB-C2 cancer cells by suppressing the expression of P-gp. To further delineate the mechanism of action of ribociclib, we conducted docking study to determine the magnitude of the interaction of ribociclib with a human homology model of the P-gp transporter (Figure 3, Figure 4). The result showed that ribociclib significantly interacts with the P-gp transporter. In addition to the surface matching and van der Waals interactions, there is a strong electrostatic interaction between the N,N-dimethylamide cluster in ribociclib and the amino acids E273 and E1129 in P-gp protein. These results, in addition to the intracellular drug accumulation data, suggest that ribociclib interacts with the drug-substrate binding pocket of P-gp, further suggesting that it could be a substrate of P-gp that inhibits the binding of other P-gp substrates, such as colchicine and doxorubicin.

Ribociclib could reverse P-gp-mediated MDR by decreasing the expression of the P-gp transporter. Western blot and IF data indicated that the incubation of KB-C2 cells with 9 µM of ribociclib for 72 h significantly decreased the expression level of the P-gp protein compared to cells incubated with vehicle (Figure 1). In contrast to our results with ribociclib, it has been
reported that abemaciclib, a CDK4/6 inhibitor, did not significantly alter the expression of the P-gp transporter in cancer cells overexpressing the P-gp transporter (Wu et al., 2017). The exact explanation for the differential effect of abemaciclib and ribociclib on the expression level of the P-gp remains to be determined. However, this could be due to differences in their intracellular accumulation and interaction with their targets. Overall, ribociclib decreases the resistance to colchicine and doxorubicin in KB-C2 cancer cells by 1) interacting with the P-gp protein and inhibiting the efflux function, thereby increasing the intracellular accumulation of these anticancer drugs and 2) decreasing the expression of the P-gp transporter, which decreases the number of transporters and thus, drug efflux.

Studies have reported that certain compounds or drugs can stimulate the ATPase activity of ABC transporters by binding to the substrate-drug binding site (Lee et al., 2019; Li et al., 2020). In this study, ribociclib produced a significant increase (3.5-fold) in the ATPase activity of the P-gp transporter (Figure 5A). This result suggests that ribociclib interacts with the substrate-drug binding site which could inhibit the binding of other P-gp transporter substrates, further inhibiting their efflux, thus increasing their intracellular levels. Similarly, voruciclib, a CDK4/6 inhibitor (Gupta et al., 2018; Gupta et al., 2018), significantly increased the ATPase activity of P-gp and inhibited the efflux of paclitaxel or mitoxantrone from human colorectal adenocarcinoma SW620/AD300 cells overexpressing P-gp and non-small cell lung cancer NCI-H460/MX20 cells overexpressing BCRP, respectively, thus reversing the MDR mediated by P-gp and BCRP, respectively (Gupta et al., 2018). However, the expression level of P-gp and BCRP was not significantly altered by the incubation of cells with 5 µM of voruciclib (Gupta et al., 2018). The difference between ribociclib and voruciclib on the expression level of P-gp could be due to their differential interaction with proteins that control the transcription of the P-gp protein, although this remains to be elucidated.

When the KB-C2 cells were cocultured with ribociclib at higher concentrations (exceeding 9 µM), reversal effects on MDR in KB-C2 cells increased. But the cell proliferation was also inhibited when using only ribociclib (instead of colchicine) higher concentrations. This could be caused by the enhanced inhibition effect on CDK4/6 by a greater number of ribociclib molecules that had entered the cells in addition to their interaction with the membrane P-gp transporters. Thus, the functions of inhibiting cancer cell proliferation and reversing P-gp mediated MDR could synergize each other during combined chemotherapy based on ribociclib and P-gp substrate drugs.

By single gene knockout using CRISPR/Cas9 technique in human epidermoid carcinoma MDR cell line KB-C2, we recently revealed that CDK6-P13K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated MDR in cancer cells (Zhang et al., 2022). CDK6 knockout downregulated P13K 110α and 110β,
and PI3K 110α/110β deficiency in-return downregulated CDK6. CDK6-PI3K axis synergizes in regulating ABCB1 expression, which further strengthened the regulation of ABCB1 over single regulation by either CDK6 or PI3K 110α/110β.

It will be instructive if we know the mechanisms of the interaction between ribociclib and P-gp, which will benefit modification of the structure of ribociclib and improving its affinity to P-gp. Till now, no study about this aspect has been reported, however, we are still making efforts on its exploration, which is an undergoing project in our laboratories.

In our laboratories, we are currently performing modification and optimization of a serial of combined drug-systems that can reverse MDR in cancers and inhibit cancer cell growth as well. Based on these studies, our tasks in the next stage will contain animal study to testify the biocompatibility and tumor killing efficacy of these drug systems.

In conclusion, the results of this study indicated that in KB-C2 cells, ribociclib inhibited the efflux of the P-gp transporter substrates, doxorubicin and colchicine and decreased the expression of the P-gp transporter, resulting in the reversal of MDR. P-gp expression was downregulated by ribociclib. Furthermore, protein docking data reveals that ribociclib binds near the P-gp transporter drug-substrate binding site and it stimulates the basal activity of the P-gp ATPase. ATPase analysis and drug accumulation experiments further demonstrated that the activity of P-gp was inhibited by ribociclib. Thus, ribociclib may be a promising inhibitor for the application in combination of anticancer therapies against solid tumor cells with P-gp mediated MDR.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

REFERENCES

Akiyama, S., Fojo, A., Hanover, J. A., Pastan, I., and Gottesman, M. M. (1985). Isolation and Genetic Characterization of Human KB Cell Lines Resistant to Multiple Drugs. Somat Cell Mol Genet 11, 117–126. doi:10.1007/BF01534700

Ambudkar, S. V. (1998). Drug-stimulatable ATPase Activity in Crude Membranes of Human MDR1-Transfected Mammalian Cells. Methods Enzymol. 292, 504–514. doi:10.1016/s0076-6879(98)92039-0

Aristizabal Prada, E. T., Nölting, S., Spoettl, G., Maurer, J., and Auernhammer, C. J. (2018). The Novel Cyclin-dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors In Vitro. Neuroendocrinology 106, 58–73. doi:10.1159/000463386

Braun, K., Hözl, G., Pusch, O., and Hengstschläger, M. (1998). Deregulated Expression of CDK2- or CDK3-Associated Kinase Activities Enhances C-Myc-Induced Apoptosis. DNA Cell Biol 17, 789–798. doi:10.1089/dna.1998.17.789

Chung, J. H., and Bunz, F. (2010). Cdk2 Is Required for P53-independent G2/M Checkpoint Control. Plos Genet. 6, e1000863. doi:10.1371/journal.pgen.1000863

Czudor, Z., Balogh, M., Bánhegyi, P., Boros, S., Breza, N., Dobos, J., et al. (2018). Novel Compounds with Potent CDK9 Inhibitory Activity for the Treatment of Myeloma. Bioorg. Med. Chem. Lett. 28, 769–773. doi:10.1016/j.bmcl.2018.01.002

Diani, L., Colombelli, C., Nachimuthu, B. T., Donnanni, R., Plevani, P., Moi, F., Falconi, M., et al. (2009). Saccharomyces CDK1 Phosphorylates Rad53 Kinase in Metaphase, Influencing Cellular Morphogenesis. J. Biol. Chem. 284, 32627–32634. doi:10.1074/jbc.M109.048157

Duan, C., Liu, Y., Lu, L., Cai, R., Xue, H., Mao, X., et al. (2015). CDK14 Contributes to Reactive Gliosis via Interaction with Cyclin Y in Rat Model of Spinal Cord Injury. J. Mol. Neurosci. 57, 571–579. doi:10.1007/s12031-015-0639-x

Feng, W., Zhang, M., Wu, Z. X., Wang, J. Q., Dong, X. D., Yang, Y., et al. (2020). Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Front. Oncol. 10, 955. doi:10.3389/fonc.2020.00955

Guo, Z., Lu, X., and Xu, H. (2020). Mir-186 Represses Progression of Renal Cell Cancer by Directly Targeting CDK6. Hum. Cell 33, 759–767. doi:10.1017/ s13577-020-00357-3

Gupta, P., Zhang, Y. K., Zhang, X. Y., Wang, Y. J., Lu, K. W., Hall, T., et al. (2018). Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Cell Physiol. Biochem. 45, 1515–1528. doi:10.1007/s00973-018-6034-0

Hirai, H., Shimomura, T., Kobayashi, M., Eguchi, T., Taniuchi, E., Fukasawa, K., et al. (2010). Biological Characterization of 2-Aminothiazole-Derived Cdk4/6 Selective Inhibitor In Vitro and In Vivo. Cell Cycle 9, 1590–1600. doi:10.4161/cc.9.8.11306

AUTHOR CONTRIBUTIONS

LZ and Z-SC conceived this study and designed the experiments; LZ, Z-SC, F-FP, and ZC sponsored the project; LZ performed MTT assay, immunofluorescence analysis, docking, drug accumulation experiments; LZ, BY, and YL performed RT-PCR; LZ and YL performed Western blot; J-QW performed ATPase assay; LZ, YL, and Z-SC analyzed the data and wrote the paper; LZ, Z-SC, YL, and F-FP revised the paper. All authors read and approved the final manuscript.

FUNDING

We thank the National Nature Science Foundation of China (21877113, 81971983, and 81874330), the Natural Science Foundation of Fujian Province (2020J0036), Six Talent Peaks of Jiangsu Province (YY-128), Wuxi Taihu Lake Talent Plan Top Talents Projects (BJ 20200001) for support on this work. This study was partially supported by Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University (New York, United States).

ACKNOWLEDGMENTS

We thank Dr. Shin-Ich Akiyama (Kagoshima University, Japan) for providing us the KB-3-1 and KB-C2 cell lines. We thank Dr. Charles R. Ashby Jr (St. John’s University) for editing the article.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.867128/full#supplementary-material
Hu, Q. L., Xu, Z. P., Lan, Y. F., and Li, B. (2020). MiR-636 Represses Cell Survival by Targeting CDK4/5/Cdk1-2 in Cervical Cancer. *Kaoxiang J. Med. Sci*. 36, 328–335. doi:10.1002/kjm.12181

Iriyama, N., Hino, H., Moriya, S., Hiramoto, M., Hatta, Y., Takei, M., et al. (2018). The Cyclin-dependent Kinase 4/6 Inhibitor, Abemaciclib, Exerts Dose-dependent Cytostatic and Cytotoxic Effects and Induces Autophagy in Multiple Myeloma Cells. *Leuk. Lymphoma* 59, 1439–1450. doi:10.1080/10428194.2017.1376741

Kaczor, A. A., Selent, J., Sanz, F., and Pastor, M. (2013). Modeling Complexes of Transmembrane Proteins: Systematic Analysis of Protein; Protein Docking Tools. *Mol. Inform.* 32, 717–733. doi:10.1002/minf.201200150

Kalaiselvi, M., Amsaveni, R., and Bhuvaneshwari, V. (2015). Molecular Docking of Kaczor, A. A., Selent, J., Sanz, F., and Pastor, M. (2013). Modeling Complexes of Transmembrane Proteins: Systematic Analysis of Protein; Protein Docking Tools. *Mol. Inform.* 32, 717–733. doi:10.1002/minf.201200150

Kwapisz, D. (2017). Cyclin-dependent Kinase 4/6 Inhibitors in Breast Cancer: P-N_terminal Domains of Cyclin-dependent Kinase Inhibitory Proteins Block the Phosphorylation of CDK2/Cyclin E by the CDK-Activating Kinase. *Biochim. Biophys. Res. Commun.* 271, 469–473. doi:10.1016/bcr.2000.2648

Robert, T., Johnson, J. L., Guichaux, R., Yaron, T. M., Bach, S., Cantley, L. C., et al. (2020). Development of A CDK10/CycM In Vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. *Front. Chem.* 8, 147. doi:10.3389/fchem.2020.00147

Sorf, A., Sucha, S., Morell, A., Novotna, E., Stauf, F., Zavrelova, A., et al. (2020). Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. *Cancers (Basel)* 12, 1596. doi:10.3390/cancers12061596

Swartz-Woollen, Z., Sage, S., and Kassir, Y. (2009). Human CDK2 Is A Functional Homolog of Budding Yeast Ime2, the Meiosis-specific Gsk-like Kinase. *Cell Cycle* 8, 647–654. doi:10.4161/cc.8.4.7843

Tai, S. T., Lin, P. M., Wu, C. F., Hung, S. K., Huang, C. I., Wang, C. C., et al. (2019). CDK4/6 Inhibitor LEE011 Is a Potential Radiation-Sensitizer in Head and Neck Squamous Cell Carcinoma: An *In Vitro* Study. *Anticancer Res.* 39, 713–720. doi:10.21873/anticanres.13167

Tripathy, D., Bardia, A., and Sellers, W. R. (2017). Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-dependent Kinase 4/6 Inhibitor in Various Solid Tumors. *Clin. Cancer Res.* 23, 3251–3262. doi:10.1158/1078-0432.CCR-16-3157

Wu, T., Chen, Z., Li, T., Yeh, C., Fang, X., Wang, F., Cheng, N., et al. (2017). Effect of Abemaciclib (LY2835219) on Enhancement of Chemotherapeutic Agents in ABCB1 and ABCG2 Overexpressing Cells In Vitro and In Vivo. *Biochim. Pharmacol.* 124, 29–42. doi:10.1016/j.bcp.2016.10.015

Wu, C. P., Huang, T. H., Hisao, S. H., Huang, Y. H., Hung, C. L., Yu, Y. J., et al. (2020). Eradiatinhibin Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. *Cancers (Basel)* 12, 1366. doi:10.3390/cancers12061366

Yang, D., Kwapisz, D., Chuan, E. E., Patel, A., Ambudkar, S. V., Chen, Z. S., et al. (2014). Tivozanib Reverses Multidrug Resistance Mediated by ABCB1 (P-Glycoprotein) and ABCG2 (BCRP). *Future Oncol.* 10, 1827–1841. doi:10.2217/fon.13.253

Yoshimura, A., Kuwazuru, Y., Sumizawa, T., Ikeda, S., Ichikawa, M., Usagawa, T., et al. (1989). Biosynthesis, Processing and Half-Life of P-Glycoprotein in A Human Multidrug-Resistant KB Cell. *Biochim. Biophys. Acta* 992, 307–314. doi:10.1016/0304-4165(89)90089-5

Zhang, L., Li, Y., Qiu, R., Chen, Z., and Li, H. (2019). The PI3K Subunits, P110β and P110δ, Are Potential Targets for Overcoming P-Gp and BCRP-Mediated MDR in Cancer. *Mol. Cancer* 19, 10. doi:10.1186/s12943-019-1112-1

Zhang, L., Li, Y., Wang, Q., Chen, Z., Li, X., Wu, Z., et al. (2020). The PI3K Subunits, P110α and P110β Are Potential Targets for Overcoming P-Gp and BCRP-Mediated MDR in Cancer. *Mol. Cancer* 19, 10. doi:10.1186/s12943-019-1112-1

Zhang, Z., Li, Y., Wu, C., Chen, Y., Chen, Z., Chen, Z.-S., et al. (2022). CDK6-PI3K Signaling Axis Is An Efficient Target for Attenuating ABCB1/P-Gp Mediated Multi-Drug Resistance (MDR) in Cancer Cells. *Mol. Cancer.* In press. doi:10.1186/s12943-022-01524-w

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Ye, Lin, Li, Wang, Chen, Ping and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.